Prospective Phase 2 Clinical Trial of Carbon Ion Radiation Therapy Combined With Chemotherapy for Locally Advanced Pancreatic Carcinoma

放射治疗 化疗 碳离子放射治疗 医学 癌 临床试验 肿瘤科 胰腺癌 相(物质) 内科学 放射科 胰腺癌 癌症 化学 有机化学
作者
Guangyuan Zhang,Xin Cai,Hong Cao,Zhan Yu,Weiwei Wang,Ying Xing,Jingfang Zhao,Qing Zhang,B. Zhang,Fei Liang,Mansoor M. Ahmed,Xiaodong Wu,Chandan Guha,Guoliang Jiang,Zheng Wang
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier BV]
卷期号:123 (4): 1061-1070 被引量:1
标识
DOI:10.1016/j.ijrobp.2025.06.3881
摘要

In locally advanced pancreatic carcinoma (LAPC), combining chemotherapy with photon radiation therapy has not demonstrated survival benefits over chemotherapy alone. Conversely, carbon ion radiation therapy (CIRT) has shown encouraging outcomes from Japanese studies. The purpose of this trial was to assess the efficacy and toxicities of CIRT combined with chemotherapy in LAPC through a prospective phase 2 clinical trial. Patients with histologically or cytologically confirmed pancreatic adenocarcinoma, locally advanced disease without gastrointestinal invasion, no distant metastasis, and who received induction chemotherapy were enrolled. The prescribed relative biological effectiveness-weighted dose of CIRT was 67.5 Gy in 15 fractions over 3 weeks, which was calculated by the local effect model version I. Chemotherapy was administered before and after CIRT. The primary endpoint was the 2-year locoregional progression-free survival rate. From 2018 to 2022, 49 patients (T4N0M0 39, T4N1-2M0 10) were enrolled. All patients underwent induction chemotherapy with a median of 6 cycles (range, 1-11 cycles), and 31 patients (63%), post-CIRT chemotherapy. The median overall survival was 24.1 months (95% CI, 19.8-28.0 months) from diagnosis, and 19.6 months (95% CI, 13.6-22.7 months) from CIRT, respectively. In addition, the 1-year and 2-year locoregional control rates were 87.9% (95% CI, 77.9%-97.9%) and 72.9% (95% CI, 56.8%-89.0%), respectively. The 1-year and 2-year locoregional progression-free survival rates were 65.3% (95% CI, 52.0%-78.6%) and 24.5% (95% CI, 12.5%-36.5%), respectively. The 1-year and 2-year distant metastasis-free survival rates were 36.7% (95% CI, 23.2%-50.2%) and 18.4% (95% CI, 7.6%-29.2%), respectively. Thirty-three patients (67%) experienced grade 1-2 acute toxicity, and 2 patients (4%) had grade 2 late toxicity. No acute or late toxicity of ≥grade 3 was observed. Although the primary endpoint was not met, this prospective clinical trial of CIRT with chemotherapy demonstrated promising results with minimal toxicities in patients with LAPC. The findings strongly advocate for prospective randomized trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
菲子笑发布了新的文献求助10
1秒前
桃子完成签到 ,获得积分10
1秒前
小巧新竹完成签到,获得积分10
1秒前
2秒前
赘婿的应助被谢尔顿采纳,获得10
2秒前
KQ2077完成签到 ,获得积分10
2秒前
顾矜的应助被tao采纳,获得10
3秒前
KKKKKKK完成签到,获得积分10
3秒前
3秒前
夹个紧完成签到,获得积分10
4秒前
所所的应助被认真白猫采纳,获得10
4秒前
4秒前
4秒前
5秒前
务实一斩发布了新的文献求助10
5秒前
无情鹏煊完成签到,获得积分10
5秒前
星辰坠于海的应助被如意语山采纳,获得50
5秒前
颜倾完成签到,获得积分10
5秒前
王大蒜完成签到,获得积分10
6秒前
7秒前
田様的应助被KKKKKKK采纳,获得10
7秒前
7秒前
一天一天完成签到 ,获得积分10
8秒前
tietie发布了新的文献求助10
8秒前
fff关闭了fff的文献求助
8秒前
8秒前
Owen的应助被舒适JIA采纳,获得10
8秒前
Halo发布了新的文献求助10
9秒前
余庆发布了新的文献求助10
9秒前
Ava的应助被qi采纳,获得10
10秒前
10秒前
10秒前
11秒前
李子发布了新的文献求助10
11秒前
11秒前
科研顺利发布了新的文献求助10
11秒前
12秒前
12秒前
GooodMa完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187652
求助须知:如何正确求助?哪些是违规求助? 9575758
关于积分的说明 21842805
捐赠科研通 7785538
什么是DOI,文献DOI怎么找? 3435073
关于科研通互助平台的介绍 2559480
邀请新用户注册赠送积分活动 2481963